Divis Lab Share Price Target Tomorrow From 2025 To 2030- Market Overview, Current Chart
Divi’s Lab is a trusted and leading pharmaceutical company from India, known for making high-quality medicines and active pharmaceutical ingredients (APIs). It serves many top global pharma companies and is respected for its clean processes, world-class manufacturing, and timely delivery. People feel confident about Divi’s Lab because it focuses on safety, innovation, and strong ethics. Divis Lab Share Price on NSE as of 17 June 2025 is 6,690.50 INR. This article will provide more details on Divis Lab Share Price Target 2025, 2026 to 2030.
Divi’s Laboratories Ltd: Company Info
- CEO: Kiran S. Divi (Jan 2020–)
- Founded: 12 October 1990
- Founder: Murali Divi
- Headquarters: India
- Number of employees: 9,741 (2024)
- Revenue: 9,073 crores INR (US$1.1 billion, 2022)
- Subsidiaries: Divi’s Laboratories Europe AG, Divis Laboratories (USA), Inc.
Divis Lab Share Price Chart
Divis Lab Share: Market Overview
- Open: 6,632.00
- High: 6,698.00
- Low: 6,615.00
- Mkt cap: 1.78LCr
- P/E ratio: 80.41
- Div yield: 0.45%
- 52-wk high: 6,862.50
- 52-wk low: 4,395.30
Divis Lab Share Price Target Tomorrow From 2025 To 2030
Here are the estimated share prices of Divis Lab for the upcoming years, based solely on market valuation, enterprise trends and professional predictions.
- 2025 – ₹6870
- 2026 – ₹9070
- 2027 – ₹11,120
- 2028 – ₹13355
- 2029 – ₹15690
- 2030 – ₹17840
Divis Lab Share Price Target 2025
Divis Lab share price target 2025 Expected target could be between ₹6850 to ₹6870. Here are 7 key factors that could influence the growth of Divi’s Laboratories (Divis Lab) share price by 2025:
1. Strong Q4–FY25 Financial Performance
In Q4 of FY25, Divis reported a 23–26% YoY rise in net profit (₹662–667 crore) and a 12% increase in revenue (₹2,536–2,585 crore), with expanding EBITDA margins
2. Robust Custom Synthesis (CDMO) Growth
The CDMO business surged ~56% YoY in Q2 FY25, boosting earnings and attracting global pharma contracts—an area poised for further expansion
3. Capacity Expansion at Kakinada Unit
Phase III greenfield plant in Kakinada is operational, with multiple tranches of capex (~₹650–700 crore each) underway. This unlocks future growth in both generic APIs and CDMO .
4. China‑Plus‑One Tailwinds
Shift of global pharma supply chains away from China benefits Divi’s—leveraging its backward integration, quality compliance, and cost efficiency in APIs and CDMO
5. GLP‑1 & Contrast Media Opportunities
Divi’s is developing peptide building blocks for the fast-growing GLP‑1 drugs and iodine-based contrast media—novel high-margin segments.
6. Favorable Analyst Outlook & Upgrades
Brokerages like Nuvama, Citi, and JM Financial recommend Buy, with 12–18 month targets around ₹7,050–7,225, reflecting confidence in growth and valuations .
7. Premium Valuation Reflecting Long‑Term Potential
Divi’s trades at high multiples (~49–60× FY26–27 EV/EBITDA), which shows investor confidence—but suggests future gains rely on strong execution and earnings delivery .
Divis Lab Share Price Target 2030
Divis Lab share price target 2030 Expected target could be between ₹17800 to ₹17840. Here are 7 key risks and challenges that could affect the share price of Divi’s Laboratories by 2030:
1. Regulatory and Compliance Risks
Divi’s operates in a highly regulated global market. Any adverse observations from agencies like the USFDA or EMA can result in import bans, slow product approvals, and damage to reputation.
2. Concentration Risk in Generic APIs
A significant part of Divi’s revenue comes from a few generic APIs. If competition rises or pricing falls in these products, overall profitability could be impacted.
3. Dependence on Global Demand & Macro Conditions
Divi’s growth is linked to global pharma trends. Any economic slowdown, geopolitical tension, or pharma spending cuts in key markets like the US and Europe may reduce demand.
4. Execution Risk in Capacity Expansion
With large capex projects like the Kakinada greenfield plant, any delay, cost overrun, or failure to ramp up capacity efficiently could limit future growth and returns.
5. Innovation and R&D Pressure
As the pharmaceutical industry moves toward complex biologics and specialty drugs, Divi’s must consistently invest in R&D to remain competitive. Falling behind in innovation could pose a long-term threat.
6. High Valuation and Market Expectations
Divi’s trades at premium valuations. If earnings growth slows or expectations aren’t met, the stock may face sharp corrections, even with minor setbacks.
7. Foreign Exchange and Raw Material Risks
Since Divi’s earns a large portion of its revenue from exports, any sharp currency fluctuations or rise in raw material prices (like solvents and intermediates) could squeeze margins.
Shareholding Pattern For Divis Lab Share
| Held By | May 2025 |
| Promoters | 51.89% |
| Flls | 18.01% |
| Dlls | 20.71% |
| Public | 9.39% |
Divis Lab Financials
| (INR) | 2025 | Y/Y change |
| Revenue | 93.60B | 19.31% |
| Operating expense | 30.69B | 15.29% |
| Net income | 21.91B | 36.94% |
| Net profit margin | 23.41 | 14.75% |
| Earnings per share | 82.53 | 36.93% |
| EBITDA | 29.68B | 34.60% |
| Effective tax rate | 24.86% | — |
Read Also:- Waaree Energies Share Price Target Tomorrow From 2025 To 2030- Market Overview, Current Chart
